<DOC>
	<DOCNO>NCT01911273</DOCNO>
	<brief_summary>The primary purpose study explore whether treatment PF-03446962 best supportive care well placebo plus best supportive care prolong survival patient affect recurrent liver cancer . In addition , study explore add PF-03446962 best supportive care safe , PF-03446962 metabolize , patient ' characteristic ( biomarkers ) may predict response PF-03446962 , PF-03446962 effect patient ' quality life .</brief_summary>
	<brief_title>A Study To Evaluate The Efficacy And Safety The Investigational Drug PF-03446962 ( A Monoclonal Antibody With Antiangiogenic Features ) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer</brief_title>
	<detailed_description>This study terminate June 24th , 2014 due change strategy PF-03446962 clinical development . There safety efficacy concern regard study behind decision terminate trial . The study temporary halt since March 10th currently patient treatment process randomize</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosis locally advance metastatic liver cancer obtain histology/cytology image Documented progression treatment sorafenib , confirm Investigator upon review appropriate imaging documentation Child Pugh Class A disease ECOG [ Eastern Cooperative Oncology Group ] Performance Status ( PS ) 0 1 Mandatory tumor biopsy study entry ( prerandomization , unless already collect sorafenib progression within 3 month enrollment systemic anticancer therapy receive ) Prior systemic treatment advance liver cancer sorafenibincluding therapy Prior local therapy within 2 week start study treatment Presence main portal vein invasion liver cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>ALK-1</keyword>
	<keyword>best supportive care</keyword>
</DOC>